Overview

Study of Efficacy and Safety of Inclisiran in Asian Participants With Atherosclerotic Cardiovascular Disease (ASCVD) or ASCVD High Risk and Elevated Low Density Lipoprotein Cholesterol (LDL-C)

Status:
Recruiting

Trial end date:
2022-09-30

Target enrollment:

Participant gender:

Summary

A multicenter study to evaluate safety and efficacy of inclisiran in Asian patients with ASCVD or ASCVD high risk and elevated LDL-C

Phase:

Phase 3

Details

Lead Sponsor:

Novartis Pharmaceuticals